Shots:Flare Therapeutics has dosed its first patient with FX-909 in P-Ib trial for the treatment of locally-advanced or metastatic urothelial cancerThe P-Ib trial will assess FX-909 (30 & 50mg; QD) in 40 pts, incl. a biomarker-defined population, building on clinical PoC achieved in P-Ia, with P-Ia data to be presented in 2025. Efficacy…

SPOTLIGHT

CXO Talks: Jed Litwiniuk & Uwe Tigör from Auxilius Pharma in a Riveting Dialogue Exchange with PharmaShots

In this fifth episode of our recently launched CXO Talks, we spoke with a distinguished panel of speakers from Auxilius Pharma, Jed Litwiniuk, the CEO, and Uwe Tigör, the CMO of the company. Auxilius Pharma is an emerging specialized pharma company aimed at developing, optimizing, and delivering well-established medications internationally. Jed & Uwe walked memory…

ByHimanshu SehgalNovember 11, 2024

Flare Therapeutics Reports First Patient Dosing in P-Ib Trial of FX-909 for Urothelial Cancer

CXO Talks: Jed Litwiniuk & Uwe Tigör from Auxilius Pharma in a Riveting Dialogue Exchange with PharmaShots

Contact US

OUR INFORMATION

FOLLOW US